Related Experiment Videos
Drug-eluting stents for emerging treatment strategies in complex lesions
Charles A Simonton1, Bruce R Brodie, B Hadley Wilson
1Sanger Clinic, PA, Carolinas Heart Institute, Charlotte, North Carolina, USA.
Insights
Drug-eluting stents (DES) show promise in complex patients, reducing restenosis in ST-elevation myocardial infarction and chronic total occlusions. Early data suggest favorable outcomes for in-stent restenosis and saphenous vein graft lesions.
Area of Science:
- Interventional Cardiology
- Biomaterials Science
Background:
- Drug-eluting stents (DES) usage has expanded beyond simple cases to high-risk patients and complex lesions.
- Emerging data suggest potential benefits of DES in specific complex patient subgroups.
Purpose of the Study:
- To evaluate the efficacy of DES in complex patient subgroups, focusing on reducing late clinical restenosis.
- To assess the safety and effectiveness of DES in ST-elevation myocardial infarction, chronic total occlusions, in-stent restenosis, and saphenous vein graft lesions.
Main Methods:
- Review of early registry reports and small clinical series for various complex patient cohorts.
- Comparison of DES outcomes with historical controls (e.g., brachytherapy) where applicable.
Main Results:
- Promising early reports in ST-elevation myocardial infarction with no increased subacute stent thrombosis and less restenosis.
- Potential for unprecedented long-term patency with DES in chronic total occlusions.
- Striking reductions in late loss and restenosis for in-stent restenosis using DES.
- Acceptable rates of complications in saphenous vein graft lesions treated with DES.
Conclusions:
- Emerging data support the use of DES in complex patient subgroups for reducing late clinical restenosis.
- Further large-scale data are anticipated to guide broader real-world application of DES in complex cases.
Abstract:
The use of drug-eluting stents (DES) has rapidly expanded from lower-risk, single-lesion procedures to include a broad spectrum of high-risk patients and complex lesions. For 4 complex patient subgroups, emerging data suggest that DES might offer an advantage for reducing late clinical restenosis. In ST elevation myocardial infarction, early registry reports are promising, with no evidence to date for an increased incidence of subacute stent thrombosis and significant trends for less restenosis. For chronic total occlusions, early, small clinical series show that DES might have unprecedented long-term patency. Initial registries of DES for in-stent restenosis reveal striking reductions in late loss and restenosis, compared with brachytherapy historical controls. The use of DES in saphenous vein graft lesions is increasing, and early registry results show a very acceptable incidence of thromboembolic complications and major adverse cardiac events. Important data regarding much larger groups of these patient cohorts will emerge over the next year, to help guide the broader application of DES in "real-world" practice.
Related Concept Videos
01:26Atherosclerosis III: Management
01:27Peripheral Artery Disease III: Interprofessional Care
01:30Acute Coronary Syndrome I: Introduction
01:27Coronary Artery Disease V: Interprofessional Care